title: One year evaluation of immunogenicity conferred by a Chinese hamster ovary cell recombinant hepatitis B vaccine in a French Polynesian newborn immunization programme.
abstract: In 1988, a hepatitis immunization programme, using a Chinese hamster ovary (CHO) cell recombinant vaccine, was implemented for newborn children in the Austral archipelago (French Polynesia). Three different schedules were used: (i) 4 vaccine doses at months (M) 0, M1, M2 and M12; (ii) 3 vaccine doses at M0, M1, M6; and (iii) 3 vaccine doses at M0, M1, M2. Results at the one year follow-up may be summarized as follows. Of 197 infants who received one or more doses of CHO-recombinant vaccine, (i) none was an HBsAg carrier; (ii) 89.5% had anti-HBs-antibody titres greater than 10 miu/ml; and (iii) 95.9% had seroconverted for at least one of the 2 antibodies studied (anti-HBs or anti-pre-S2). After 2 doses (M0, M1), anti-HBs seroconversion rate and geometric mean titre were, respectively, 82.6% and 98.47 miu/ml. After 3 doses, seroconversion rates and geometric mean titres were, respectively, 91.1% and 200.59 miu/ml using schedule M0, M1, M2, and 100% and 1253.4 miu/ml using the M0, M1, M6 schedule. None of the 7 vaccinated neonates born to HBsAg/HBeAg positive mothers was found to be an HBsAg carrier. These preliminary results indicate that, in field conditions, vaccination with a CHO-recombinant vaccine resulted in high immunogenicity.
authors.affiliation: Institut Territorial de Recherches Médicales Louis Malardé, Papeete, Tahiti, French Polynesia.
authors.forename: A
authors.initials: A
authors.lastname: Spiegel
authors.forename: J P
authors.initials: JP
authors.lastname: Boutin
authors.forename: J L
authors.initials: JL
authors.lastname: Cartel
authors.forename: S
authors.initials: S
authors.lastname: Chanteau
authors.forename: R
authors.initials: R
authors.lastname: Cardines
authors.forename: P
authors.initials: P
authors.lastname: Saliou
authors.forename: J F
authors.initials: JF
authors.lastname: Roux
mesh_terms: D005260:Female; D006509:Hepatitis B / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000032:analysis; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D011114:Polynesia; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000627:therapeutic use; D014761:Viral Hepatitis Vaccines / Q000627:therapeutic use*
chemical_list: D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D014614:Vaccines, Synthetic; D014761:Viral Hepatitis Vaccines